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Although certain chemokines and their receptors guide homeostatic recirculation of T cells 
and others promote recruitment of activated T cells to inflammatory sites, little is known of 
the mechanisms underlying a third function, migration of Foxp3
 
 
 
 regulatory T (T reg) cells 
to sites where they maintain unresponsiveness. We studied how T reg cells are recruited to 
cardiac allografts in recipients tolerized with CD154 monoclonal antibody (mAb) plus 
donor-specific transfusion (DST). Real-time polymerase chain reaction showed that 
intragraft Foxp3 levels in tolerized recipients were 
 
 
 
100-fold higher than rejecting 
allografts or allografts associated with other therapies inducing prolonged survival but not 
tolerance. Foxp3
 
 
 
 cells were essential for tolerance because pretransplant thymectomy or 
peritransplant depletion of CD25
 
 
 
 cells prevented long-term survival, as did CD25 mAb 
therapy in well-functioning allografts after CD154/DST therapy. Analysis of multiple 
chemokine pathways showed that tolerance was accompanied by intragraft up-regulation of 
CCR4 and one of its ligands, macrophage-derived chemokine (CCL22), and that tolerance 
induction could not be achieved in CCR4
 
 
 
/
 
 
 
 recipients. We conclude that Foxp3 expression 
is specifically up-regulated within allografts of mice displaying donor-specific tolerance, 
that recruitment of Foxp3-expressing T reg cells to an allograft tissue is dependent on the 
chemokine receptor, CCR4, and that, in the absence of such recruitment, tolerizing 
strategies such as CD154 mAb therapy are ineffectual.
 
Previous studies have demonstrated a role for
regulatory T (T reg) cells in promotion of al-
lograft tolerance (1–6). However, little is known
concerning the relative importance of naturally
occurring T reg cells versus T reg cells induced
posttransplantation (post-Tx), the signals re-
sponsible for T reg cell generation and function
in vivo, and how T reg cells home to key sites.
Study of T reg cells in vivo is complicated by a
paucity of phenotypic markers to distinguish
activated effector T cells from T reg cells
post-Tx. CTL antigen-4, glucocorticoid-induced
TNF receptor (GITR), and the cytokines
TGF-
 
 
 
 and IL-10 have each been linked with,
but not proven entirely specific for, T reg cells
(1, 7–9). In contrast, Foxp3, a gene that en-
codes a forkhead/winged helix transcription
factor Scurfin, is required for T reg cell devel-
opment and studies support its utility as a
marker of T reg cells (10, 11).
Of the multiple forms of costimulation
blockade that can promote long-term en-
graftment in rodent models, only targeting of
CD40–CD154 interactions, typically in con-
junction with donor-specific transfusion (DST),
has proven widely successful in promoting
donor-specific tolerance (12–14). Indeed, in
the absence of knowledge of the signals
required for induction of T reg cells, it is con-
ceivable that some forms of costimulatory
blockade may promote long-term allograft sur-
vival but prove detrimental to formal tolerance
induction. In the case of CD154 mAb-linked
tolerance, well-functioning allografts consis-
tently show host mononuclear cell infiltration
but an absence of target organ injury, suggest-
ing a potentially active process of regulation
within the graft (15). The presence of Foxp3
 
 
 
cells in tolerized grafts after CD4 mAb block-
ade has been demonstrated in skin allograft
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studies (4, 5). However, despite in vitro studies indicating
that various chemokine receptors are expressed by human
and murine T reg cells, nothing is known about the
chemokine pathways that promote homing of T reg cells
to allografts.
We now provide evidence that Foxp3 expression is de-
tected within cardiac allografts and that expression is mark-
edly enhanced by therapies that promote tolerance induc-
tion. In addition, we show that naturally occurring T reg
cells provide intragraft Foxp3 expression, and that their
homing to allografts is both CCR4 dependent and required
for allograft tolerance.
 
RESULTS AND DISCUSSION
High Foxp3 expression after CD154 mAb therapy
 
We undertook serial analysis of Foxp3 levels in a standard
murine vascularized allograft model across a full MHC mis-
match. Splenic Foxp3 mRNA levels decreased progressively
post-Tx but increased in cardiac allografts (Fig. 1 a). In-
creases in graft Foxp3 were not simply responses to surgery
or ischemia/reperfusion injury as levels in isografts were far
less than allografts (Fig. 1 b). However, allograft Foxp3 levels
in untreated recipients at 7 d post-Tx were dwarfed com-
pared with grafts associated with CD154 mAb/DST therapy
(Fig. 1 b). Expression for 
 
 
 
60 d after Tx was also shown by
Northern analysis (Fig. 1 c). Foxp3 protein was localized to a
subset of infiltrating mononuclear cells in allografts of mice
treated with CD154 mAb/DST (Fig. 1 d). These data indi-
cate that, whereas Foxp3
 
 
 
 cells traffick to sites of active im-
munity, far higher levels are seen at the same sites and persist
long-term in allograft recipients treated with CD154-directed
costimulation blockade.
 
Presence of intragraft Foxp3
 
 
 
 cells varies according to the 
therapeutic protocol
 
We evaluated whether Foxp3 expression was a common
feature in long-surviving allografts, regardless of the thera-
peutic protocol. Recipients treated with CD154/DST had
permanent allograft survival (
 
 
 
100 d) and accepted second
donor-strain cardiac allografts without any additional ther-
apy (Fig. 2 a), but rejected normally third-party donor al-
lografts (not depicted). We noted previously that treatment
of CD28
 
   
 
 recipients with anti–inducible costimulator
(ICOS) mAb also led to permanent engraftment (
 
 
 
100 d;
reference 16), and now found that such long-term recipi-
ents did not show evidence of donor-specific tolerance
when challenged with a second donor-strain cardiac al-
lograft (Fig. 2 a). The presence of CD25
 
 
 
 cells was essential
for tolerance induction using CD154/DST for the follow-
ing reasons: (a) thymectomy plus CD25 mAb therapy de-
pleted resting CD4
 
 
 
CD25
 
 
 
 T reg cells and prevented
long-term allograft survival and (b) depletion of the same
cell population in recipients bearing well-functioning car-
diac allografts after CD154/DST therapy restored allograft
rejection (Fig. 2 a, inset).
Figure 1. Post-Tx Foxp3 expression. (a) qPCR analysis showed a 
progressive decrease in splenic Foxp3 mRNA (left, mean   SD) and an 
increase in associated cardiac grafts (right); expression shown relative to 
levels at 7 or 3 d post-Tx, respectively. (b) Comparison at 7 d post-Tx 
showed increases in allograft Foxp3 mRNA (qPCR, mean   SD) were 
 5-fold that of C57BL/6 isografts (left), whereas levels in grafts from 
recipients treated with CD154 mAb/DST therapy were  100-fold higher 
than control grafts (right); expression in each panel is relative to native 
heart. (c) Confirmation of intragraft Foxp3 mRNA expression by Northern 
analysis, comparing expression in control (C) normal hearts, acutely reject-
ing (day 7) allografts or serially harvested isografts versus allografts from 
hosts treated with CD154 mAb/DST as indicated. (d) Foxp3 staining was 
exceedingly rare in allografts undergoing acute rejection (left), but readily 
detected as Foxp3  mononuclear cells in mice treated with CD154 mAb/DST; 
immunoperoxidase labeling of hematoxylin-stained cryostat sections. 
Original magnification,  250 (inset shows lack of staining with Foxp3 
peptide-absorbed antibody). 
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These data suggested the utility of comparing two proto-
cols that induced permanent allograft survival but differed in
their ability to induce allograft tolerance. qPCR analysis of
cardiac allografts showed that high levels of Foxp3 mRNA
expression were restricted to mice receiving the tolerizing
CD154/DST protocol (Fig. 2 b). The large differences in in-
tragraft Foxp3 expression were not due to differences in leu-
kocyte infiltration as levels of CD3 transcripts in rejecting al-
lografts versus those destined for long-term allograft survival
varied only two- to threefold (Fig. 2 b). Moreover, long-
surviving (
 
 
 
100 d) donor-strain cardiac allografts, but not
acutely rejected third-party cardiac allografts, in mice whose
first allografts were performed under CD154 mAb/DST
coverage also showed high intragraft Foxp3 expression (un-
published data).
Previous studies demonstrated that CD28 costimulation is
important for optimal development and maintenance of T
reg cells in thymus and periphery (17), and that ICOS block-
ade impairs the functions of Tr1-type T reg cells (9). Consis-
tent with this, naive CD28
 
   
 
 mice had 
 
 
 
30% of the thy-
mic and splenic CD4
 
 
 
CD25
 
 
 
 cells of wild-type controls,
CD4
 
 
 
CD25
 
 
 
 cells were decreased by 
 
 
 
50% in ICOS
 
   
 
mice compared with controls, and qPCR showed markedly
decreased expression of Foxp3 in CD28
 
   
 
 and ICOS
 
   
 
mice (Fig. 2 c). Hence, decreased intragraft expression of
Foxp3 in CD28
 
   
 
 recipients treated with anti-ICOS mAb at
least partially reflects impaired production of Foxp3
 
 
 
 T reg
cells. We do not know yet if therapy with CTL antigen-4–
Ig, which interrupts CD28–B7 interactions and when used in
conjunction with DST can promote long-term allograft sur-
vival, results in alterations in intragraft Foxp3 expression.
 
Foxp3 expression post-Tx does not correlate with T reg cell 
markers or cytokine expression
 
Comparison by qPCR at 7 d post-Tx showed allografts in
untreated recipients had the highest levels of CD25 and
GITR expression (Fig. 3 a). Although both CD25 and
GITR are used as markers of T reg cells, their expression is
increased upon T cell activation, rendering them of limited
use post-Tx. Indeed, elevated levels of intragraft GITR in
untreated recipients are consistent with a role for the GITR–
GITR ligand interaction in reversing the suppressive activity
of T reg cells and providing positive costimulatory signals to
responder T cells (18).
We also sought an association between intragraft mRNA
levels of key cytokines and Foxp3 expression. Although no as-
sociation with IL-2, IFN-
 
 
 
, or IL-4 was apparent (unpublished
data), the TGF-
 
 
 
 and IL-10 findings were of interest given re-
cent literature. The relation of T reg cells that constitutively
express Foxp3, so-called naive T reg cells, to T reg cells that
arise in the periphery, “induced” T reg cells, is unclear. TGF-
 
 
 
Figure 2. Foxp3, T reg cell, and costimulation blockade.
 
 (a) CD154/
DST induced long-term cardiac allograft survival and donor-specific toler-
ance, whereas CD28
 
   
 
 recipients treated with neutralizing anti-ICOS mAb 
also accepted primary cardiac allografts long term but rejected second 
donor allografts. Inset shows how thymectomy and CD25 mAb therapy 
prevents long-term allograft survival despite CD154/DST therapy (left), 
and that CD25
 
 
 
 cells are also required for maintenance of allograft sur-
vival (right) because CD25 mAb therapy beginning at day 35 restores al-
lograft rejection. (b) Levels of Foxp3 and CD3 mRNA (qPCR, mean 
 
 
 
 SD) in 
day 7 cardiac allografts. (c) Flow cytometry showing decreased CD4
 
 
 
CD25
 
 
 
 
cells in thymic and splenic samples of control, CD28
 
   
 
 or ICOS
 
   
 
 mice; 
numbers are percentage of CD4
 
 
 
CD25
 
 
 
 cells within gates set using an 
CD25 isotype mAb. (d) Analysis of corresponding Foxp3 mRNA (qPCR) with 
expression shown relative to levels in samples from CD28
 
   
 
 mice; results 
are representative of three independent experiments. 
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promotes conversion of naive T cells to T reg cells via in-
duction of Foxp3 but does not promote expansion of murine
naive T reg cells in vitro (19, 20) and, in contrast with induced
T reg cells, naive T reg cells require cell contact to exert inhib-
itory effects (19, 21). Our qPCR analysis failed to show a cor-
relation between Foxp3 (Fig. 2 b) and TGF-
 
 
 
 mRNA intra-
graft expression (Fig. 3 a), and though IL-10 levels were
markedly elevated in tolerized recipients, they were also high
in allografts of untreated mice (Fig. 3 a). High levels of TGF-
 
 
 
and IL-10 in allografts harvested at 7 d from untreated recipi-
ents likely reflect the intense inflammatory response occurring
at this point, resulting in graft destruction. Analyses at later
time points are clearly required to assess the nature of intragraft
cytokine expression and its relationship to tolerance induction.
However, at least 7 d post-Tx, the current data involving
mRNA profiling, allograft survival, and effects of CD25
 
 
 
 cell
Figure 3. Intragraft mRNA expression of immunoregulatory 
molecules and chemokine pathways at day 7 post-Tx. (a) Intragraft 
levels of CD25, GITR, TGF- , and IL-10 did not correlate with selective high 
Foxp3 expression in CD154 mAb/DST grafts. (b) Comparison of intragraft 
chemokine receptor expression. (c) Intragraft expression of CCR4 (MDC, 
TARC) and CCR8 (TCA3) ligands. qPCR results, which are shown relative 
to expression in native hearts, are representative of three independent 
experiments. 
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depletion are most consistent with expansion of a subset of
Foxp3
 
 
 
, likely naive T reg cells that do not necessarily appear
to require TGF-
 
 
 
 or IL-10 for growth or function.
 
Foxp3
 
 
 
 T reg cell recruitment and tolerance induction is 
CCR4 dependent
 
Previous studies in this model have shown that specific
chemokine/chemokine receptor pathways recruit host effec-
tor cells to allografts and are key to allograft rejection (22).
Therefore, we assessed whether any chemokine receptors
were linked with homing of T reg cells post-Tx. As antici-
pated (22), expression of the chemokine receptors, CCR2,
CCR5, and CXCR3, were highest in rejecting allografts,
and their levels in allografts destined for long-term survival
were equivalent to, or below, levels in isografts (Fig. 3 b),
but two exceptions to this pattern were apparent.
First, the chemokine receptor, CCR4, was preferentially
expressed in allografts from CD154/DST-treated recipients
(Fig. 3 b) that expressed the most Foxp3. Moreover, serial
analysis of recipient spleens by qPCR on days 3, 5, and 7
post-Tx suggested that, like Foxp3
 
 
 
 cells, CCR4
 
 
 
 cells
leave the spleen and migrate to the graft (unpublished data).
There was also increased expression of one of the two main
CCR4 ligands, macrophage-derived chemokine (CCL22),
but not thymus- and activation-regulated chemokine
(TARC; CCL17), in CD154 mAb/DST-treated grafts (Fig.
3 c). The basis for this relatively selective expression of one
ligand over the other is unknown. However, after submis-
sion of our paper, a study of patients with ovarian carcinoma
was published that showed that host responses to the tumor
cells were impaired by local Foxp3
 
 
 
 CCR4
 
 
 
 T reg cells that
were recruited as a result of tumor production of MDC and
not TARC (23).
Second, and less strikingly, although levels of CCR8
were far higher in rejecting allografts than those harvested
from mice receiving either costimulation blockade protocol,
comparison of just the latter showed a relative preponder-
ance of expression of CCR8 (Fig. 3 b) and its ligand, TCA3
(Fig. 3 c) in recipients treated with CD154 mAb/DST.
Among various receptors, human CD4
 
 
 
CD25
 
 
 
 T reg cells
are known to express CCR4 and CCR8 and display chemo-
tactic responses to their ligands, such as MDC and I-309 (the
human TCA3 homologue), respectively (24), leading us to
further consider the potential importance of the CCR4 and
CCR8 pathways in our model.
Comparison of purified CD4
 
 
 
CD25
 
 
 
 and CD4
 
 
 
CD25
 
 
 
T cells by qPCR confirmed expression of Foxp3, CCR4,
and CCR8 by CD4
 
 
 
CD25
 
 
 
 cells (Fig. 4 a), and expression
of CCR4 by T reg cells was markedly enhanced upon CD3/
CD28 mAb-induced activation (not depicted). Neutraliza-
tion of TCA3 had no effect on the tempo of allograft rejec-
tion or on the ability of CD154 mAb/DST to promote
long-term graft survival (Fig. 4 b). In contrast, although
CCR4
 
   
 
 allograft recipients rejected their grafts at the nor-
mal rate, CCR4
 
   
 
 recipients failed to show prolonged graft
survival despite CD154 mAb/DST therapy (Fig. 4 b). Al-
lografts harvested from CCR4
 
   
 
 recipients at 7 d post-Tx
had markedly decreased expression of Foxp3
 
 
 
 mRNA (Fig.
4 c), despite levels of T cell infiltration reflected in CD3
Figure 4. Key role of CCR4 in T reg cell recruitment and tolerance 
induction. (a) qPCR analysis of Foxp3, CCR4, and CCR8 mRNA expression 
by CD4 CD25  versus CD4 CD25  T cells; cells were isolated using mag-
netic beads to  95% purity. Data are expressed as relative to levels in 
CD4 CD25  cells and are representative of three separate experiments. 
(b) Targeting of TCA3 using a neutralizing mAb had no effect on allograft 
rejection in wild-type recipients or long-term allograft survival when ad-
ministered in conjunction with CD154 mAb/DST therapy. In contrast, CCR    
recipients rejected allograft normally and could not be tolerized using 
CD154 mAb/DST therapy. (c) Analysis by qPCR of intragraft levels of Foxp3, 
CD3, and CD25 mRNA expression at day 7 post-Tx, showing marked reduc-
tion in intragraft Foxp3 but not CD3 or CD25 in CCR4    versus control 
mice treated with CD154 mAb/DST; results are shown relative to expression 
in native hearts and are representative of three independent experiments. 
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transcripts, which were broadly comparable between reject-
ing allografts in CCR4
 
   
 
 mice and tolerized grafts in con-
trol mice. Associated analysis of CD25 expression demon-
strated its limited utility as a marker of T reg cells within the
first week post-Tx because levels of CD25 mRNA were
somewhat enhanced in CCR4
 
   
 
 recipients, consistent with
expression by activated effector T cells mediating acute al-
lograft rejection.
Failure of tolerance induction in CCR4
 
   
 
 mice was un-
likely to be due to defects in the immune repertoire of these
animals as we found the numbers and function of T reg cells
in CCR4
 
   
 
 mice were comparable to that of wild-type
mice (Fig. 5, a–c). Furthermore, CCR4
 
   
 
 mice displayed
intact Th1 immunity, rejecting cardiac allograft similarly to
controls, and are known to develop normal Th2-type im-
mune responses (25).
In summary, our data provide new insights into the
mechanisms of tolerance induction after costimulation
blockade. Strategies involving CD154 but not CD28/
ICOS costimulation blockade induced donor-specific tol-
erance in association with trafficking into the graft of a
population of CD4
 
 
 
CD25
 
 
 
 T reg cell–expressing Foxp3.
This trafficking to the allograft is also required for mainte-
nance of allograft tolerance. Lastly, expression profiles and
Figure 5. Numbers and function of T reg cells in CCR4 /  mice are 
comparable to WT controls. (a) FACS analysis of CD25  expression by 
CD4  cells from naive thymus, and corresponding qPCR analysis of Foxp3 
mRNA expression in whole thymus from WT and CCR4    mice. (b) FACS 
analysis of CD25  expression by CD4  cells in naive spleen and correspond-
ing qPCR analysis of Foxp3 mRNA expression in whole spleen. (c) CFSE-
labeled CD4 CD25  responder T cells exhibited decreased CD3 mAb-
induced CFSE proliferation in the presence of CD4 CD25  T reg cells from 
either WT or CCR4    mice at the indicated ratios, as compared with no T 
reg cells added. (right) Histograms show the results of quantitation of the 
absolute number of responder CD4 CFSE  cells in the absence and pres-
ence of T reg cells from WT and CCR4    mice.JEM VOL. 201, April 4, 2005 1043
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mechanistic studies indicate that migration of T reg cells to
cardiac allografts after costimulation blockade with CD154/
DST in this model is uniquely dependent upon the CCR4
chemokine receptor pathway.
MATERIALS AND METHODS
Surgery.  We performed heterotopic vascularized cardiac allografting (15)
using 6–8 wk BALB/c (H-2d) donors and wild-type, CD28 /  (26),
ICOS /  (16), or CCR4 /  (25) C57BL/6 (H-2b) recipients (n   4–6
grafts/group). Rejection, defined as cessation of ventricular contractions,
was confirmed by histology. C57BL/6 mice (4–6 wk) were thymectomized
as described previously (27). Mice were housed in specific pathogen-free
conditions and studied using a protocol approved by the Institutional Ani-
mal Care and Committee of the Children’s Hospital of Philadelphia.
Flow cytometry. T cells from thymic and splenic samples were analyzed
using CD4-FITC and CD25-PE (BD Biosciences) mAb conjugates or iso-
type controls (28). CD4 CD25  and CD4 CD25  T cells were isolated
from splenic samples ( 95% purity) by negative selection using the mag-
netic cell separation system (MACS), using the manufacturer’s recommen-
dations (Miltenyi Biotec).
Therapies. Allografted mice received CD154 mAb (MR1, Bio-Express,
250  g) plus i.v. DST (5   106 cells; reference 15), control hamster IgG, or
DST alone at surgery; anti-ICOS mAb (12A8, 200  g, i.p.; reference 16); or
control rat IgG every other day for 14 d. The contribution of CD25  cells
to tolerance was assessed with a depleting CD25 mAb (PC61): (a) thymecto-
mized mice were treated with CD25 mAb (250  g, i.p., two doses); (b) al-
lograft recipients were treated with CD25 mAb on days 0, 2, and 4 post-Tx;
or (c) allograft recipients with well-functioning grafts after CD154/DST
therapy were treated at 35 and 37 d post-Tx. Efficacy of CD25  cell deple-
tion was monitored by flow cytometry using a second CD25 mAb (7D4).
We neutralized the CCR8 ligand, TCA3 (CCL1), with a hamster mAb
(B12D6; reference 29), using 200  g daily i.v. for 14 d post-Tx.
RNA studies. For quantitative PCR analysis (qPCR), RNA extraction,
reverse transcription, cDNA amplification using specific primer and probe
sequences for target genes (TaqMan PDAR; Applied Biosystems), and stan-
dardization were performed as described previously (28). Full-length 1,312-
bp Foxp3 cDNA was amplified from total thymus RNA using forward
5 -GAACCCAATGCCCAACCCTAG-3  and reverse 5 -TTCTTGGT-
TTTGAGGTCAAGGG-3  primers, and used for Northern analysis (16).
Immunopathology. Allograft histology was assessed in hematoxylin and
eosin– and elastin-stained paraffin sections, and infiltrating cells were ana-
lyzed by immunoperoxidase using rat anti–mouse mAbs (16). Foxp3 was
detected with an affinity-purified rabbit antibody generated against a 13-
mer peptide TFPRSGTPRKDSN corresponding to amino acids 169–181
of mouse Foxp3; a single band of  52 kD was seen by Western blotting of
mouse thymocytes.
T cell proliferation assays. CD4 CD25  and CD4 CD25  T cells plus
APCs were isolated from spleen and lymph node samples by negative selec-
tion (MACS; reference 28); 5   104 responder CD4 CD25  cells were la-
beled with carboxyfluorescein succinimidyl ester (CFSE), cocultured with
equal numbers of APCs in the presence of 0.5  g/ml CD3 with or without
CD4 CD25  T reg cells at the indicated ratios, and CFSE proliferation was
assessed 48 h later.
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